Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Harrington

Showing results (111-120 of 197) with videos related to

Pageof 20
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 28, 2015
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune ResponsesKarishma Rajani, Christopher Parrish, Timothy Kottke, et al.
Future Oncology (London, England)|January 16, 2025
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumorsKevin Harrington, Shigehisa Kitano, Valentina Gambardella, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 28, 2011
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapyTimothy Kottke, John Chester, Elizabeth Ilett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporterInge Peerlinck, Andrew Merron, Patrick Baril, et al.
Cancer Research|June 18, 2003
Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapyMarka Crittenden, Michael Gough, John Chester, et al.
British Journal of Cancer|August 16, 2017
Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinomaJen Y Lee, Isaac Garcia-Murillas, Rosalind J Cutts, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2008
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic VirusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Nature Biotechnology|March 20, 2012
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanomaJose Pulido, Timothy Kottke, Jill Thompson, et al.
Nature Biotechnology|August 10, 2004
A simple method to cure established tumors by inflammatory killing of normal cellsGregory A Daniels, Luis Sanchez-Perez, Rosa Maria Diaz, et al.
Pageof 20

Showing results (111-120 of 197) with videos related to

Sort By:
Pageof 20
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 28, 2015
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune ResponsesKarishma Rajani, Christopher Parrish, Timothy Kottke, et al.
Future Oncology (London, England)|January 16, 2025
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumorsKevin Harrington, Shigehisa Kitano, Valentina Gambardella, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 28, 2011
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapyTimothy Kottke, John Chester, Elizabeth Ilett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporterInge Peerlinck, Andrew Merron, Patrick Baril, et al.
Cancer Research|June 18, 2003
Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapyMarka Crittenden, Michael Gough, John Chester, et al.
British Journal of Cancer|August 16, 2017
Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinomaJen Y Lee, Isaac Garcia-Murillas, Rosalind J Cutts, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2008
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic VirusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Nature Biotechnology|March 20, 2012
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanomaJose Pulido, Timothy Kottke, Jill Thompson, et al.
Nature Biotechnology|August 10, 2004
A simple method to cure established tumors by inflammatory killing of normal cellsGregory A Daniels, Luis Sanchez-Perez, Rosa Maria Diaz, et al.
Pageof 20